Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) – Analysts at Zacks Research reduced their Q1 2024 EPS estimates for shares of Alnylam Pharmaceuticals in a research note issued to investors on Thursday, June 1st. Zacks Research analyst A. Chakroborty now anticipates that the biopharmaceutical company will earn ($1.58) per share for the quarter, down from […]
The Manufacturers Life Insurance Company decreased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 59.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 343,220 shares of the biopharmaceutical company’s stock after selling 495,795 shares during the quarter. […]
American Century Companies Inc. grew its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 1.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 699,795 shares of the biopharmaceutical company’s stock after acquiring an additional 6,788 shares […]
Simplify Asset Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 8.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,392 shares of the biopharmaceutical company’s stock after purchasing an additional 112 shares during the period. Simplify […]
StockNews.com began coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) in a research report sent to investors on Thursday. The brokerage issued a buy rating on the biopharmaceutical company’s stock. A number of other brokerages have also commented on ALNY. Canaccord Genuity Group lowered their price target on Alnylam Pharmaceuticals from $310.00 to […]